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1.1. Anatomy
1.1.1. Primary site
Cases should be classiﬁed as carcinomaof the vulvawhen the prima-
ry site of growth is in the vulva. Any lesion that involves both the vagina
and vulva (i.e. crosses the hymenal ring) should be classiﬁed as a carci-
noma of the vulva. Tumors that present in the vulva as secondary
growths, from either a genital or extragenital site, should be excluded.
Malignant melanoma should be reported separately. There must be
histologic conﬁrmation of the cancer.
1.1.2. Nodal stations
The inguinal and femoral nodes are the ﬁrst sites of regional spread.
1.1.3. Metastatic sites
Patients who have extrapelvic metastases or who have involvement
of pelvic lymph nodes (external, hypogastric, obturator, and common
iliac) are classiﬁed as having stage IVB disease.
1.2. Surgical staging classiﬁcation
The staging system for vulvar cancer has been based on surgicalﬁnd-
ings since 1988. The ﬁnal diagnosis is dependent upon thorough histo-
pathologic evaluation of the operative specimen (vulva and lymph
nodes). Various modiﬁcations have been made over time, with a subdi-
vision of Stage I added in 1994. The FIGO staging of vulvar carcinoma
was last changed in 2009 by the FIGO Committee on Gynecologic
Oncology [1], to give better prognostic discrimination between stages
(Table 1). Table 2 compares the FIGO stagingwith the Union of Interna-
tional Cancer Control “TNM” classiﬁcation.
1.2.1. Histopathologic types
Approximately 80% of cases are squamous cell carcinomas, andmany
cases, particularly in younger women, are HPV related. Melanomas are
the second most common cancer seen in cancer centers, although
community-based studies have reported basal cell carcinomas to be the
second most common vulvar cancer [2]. The histopathologic types are:
• squamous cell carcinoma
• melanomahttp://dx.doi.org/10.1016/j.ijgo.2015.06.002
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).• verrucous carcinoma
• Paget’s disease of vulva
• adenocarcinoma, not otherwise speciﬁed (NOS)
• basal cell carcinoma, NOS
• Bartholin’s gland carcinoma.
1.2.2. Histopathologic grades (G)
• GX: Grade cannot be assessed
• G1: Well differentiated
• G2: Moderately differentiated
• G3: Poorly or undifferentiated.
2. Introduction
Carcinoma of the vulva is an uncommon tumor, representing about
4% of gynecologic malignancies. Because of the relatively small experi-
ence of individual institutions, randomized trials of therapeutic ap-
proaches are uncommon, and most studies are based on retrospective
clinicopathologic reviews [3].
It is predominantly a disease of postmenopausal women, with the
age-speciﬁc incidence increasing with increasing age. Although the
external location of the vulva should encourage early presentation,
vulvar cancers are often advanced at the time of diagnosis.
Most squamous carcinomas occur on the labia majora, but the labia
minora, clitoris, and perineum may also be primary sites.
Vulvar intraepithelial neoplasia (VIN), a precursor lesion in some
cases, tends to occur in younger women and may be associated with
similar lesions of the cervix and vagina. A new classiﬁcation of squa-
mous VIN was introduced by the International Society for the Study of
Vulvovaginal Disease (ISSVD) in 2004 [4]. The term VIN 1 is no longer
used, and VIN 2 and 3 are simply called VIN. There are two types of
VIN: (1) VIN, usual type (warty, basaloid, and mixed), which is HPV-
related in most cases; and (2) VIN, differentiated type, which is seen
particularly in older women, and is often associated with lichen
sclerosus and/or squamous hyperplasia. The incidence of VIN, usual
type, and the incidence of invasive vulvar cancer in premenopausal
women should both decrease signiﬁcantly with increasing use of
HPV vaccination.Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
Table 1
FIGO staging of carcinoma of the vulva.
FIGO
Stage
Description
I Tumor conﬁned to the vulva
IA Lesions ≤ 2 cm in size, conﬁned to the vulva or perineum and with stromal
invasion ≤ 1.0 mma, no nodal metastasis
IB Lesions N 2 cm in size or with stromal invasion N 1.0 mma, conﬁned to the
vulva or perineum, with negative nodes
II Tumor of any size with extension to adjacent perineal structures (lower
third of urethra, lower third of vagina, anus) with negative nodes
III Tumor of any size with or without extension to adjacent perineal
structures (lower third of urethra, lower third of vagina, anus) with
positive inguinofemoral nodes
IIIA (i) With 1 lymph node metastasis (≥5 mm), or
(ii) With 1–2 lymph node metastasis(es) (b5 mm)
IIIB (i) With 2 or more lymph node metastases (≥5 m), or
(ii) With 3 or more lymph node metastases (b5 mm)
IIIC With positive nodes with extracapsular spread.
IV Tumor invades other regional (upper 2/3 urethra, upper 2/3 vagina), or
distant structures
IVA Tumor invades any of the following:
(i) upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa,
or ﬁxed to pelvic bone, or
(ii) ﬁxed or ulcerated inguinofemoral lymph nodes
IVB Any distant metastasis including pelvic lymph nodes
a The depth of invasion is deﬁned as themeasurement of the tumor from the epithelial–
stromal junction of the adjacent most superﬁcial dermal papilla to the deepest point of
invasion.
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tion therapy and, to a lesser extent, chemotherapy have been progres-
sively integrated into the treatment protocol over the past 30 years.
Therefore, management has evolved into an individualized multidisci-
plinary approach, and patients should be referred centrally to a gyneco-
logical cancer centerwhere all relevant expertise is available [5,6]. Level
of Evidence B
3. Screening
There is no screening procedure for vulvar cancer. However, patients
with a past history of cervical or vaginal cancer should have inspection
of the vulva, with or without colposcopic examination, as part of their
regular follow-up. Patients with lichen sclerosus or a past history of
VIN should also be kept under regular surveillance, and taught to under-
take regular self-examination with a mirror.
4. Squamous cell carcinoma
4.1. Presenting symptoms
Vulvar cancermay be asymptomatic, butmost patients presentwith
a vulvar lump or ulcer, whichmay ormay not be painful. There is often a
long-standing history of pruritus, which may be due to associatedTable 2
Cancer of the vulva: FIGO staging compared with TNM classiﬁcation.
FIGO Stage Union for International Cancer Control (UICC)
T (tumor) N (lymph nodes) M (metastasis)
I T1 N0 M0
IA T1a N0 M0
IB T1b N0 M0
II T2/T3 N0 M0
IIIA T1, T2, T3 N1a, N1b M0
IIIB T1, T2, T3 N2a, N2b M0
IIIC T1, T2, T3 N2c M0
IVA T4 N0–N2 M0
IVB Any T N3 M0vulvar dystrophy. Bleeding or discharge is an occasional presenting
symptom, and patients with advanced disease may present with a
lump in the groin caused by metastases to groin lymph nodes.4.2. Diagnosis
If the disease appears to be entirely intraepithelial, initial assessment
should consist of multiple biopsies to exclude an invasive focus. A 3 or
4 mm Keyes biopsy instrument is ideal for this purpose. Patients with
multifocal lesions should have biopsies taken from several lesions.
If there appears to be invasive cancer present, a wedge or Keyes bi-
opsy under local anesthesia in the ofﬁce is usually sufﬁcient to conﬁrm
the diagnosis. The biopsy should include some underlying stroma.
For small tumors, it is preferable not to excise the entire lesion at the
time of biopsy because this makes it more difﬁcult to plan the subse-
quent deﬁnitive resection.
If the lesion is 2 cm or less in diameter and depth of stromal inva-
sion is less than or equal to 1 mm on the initial biopsy, radical local
excision of the lesion must be undertaken to allow serial sectioning to
properly assess the depth of invasion. If there is still no focus found
with a depth of invasion greater than 1 mm, this excision will also be
the deﬁnitive treatment [3].4.3. Investigations
(1) Cervical cytology, if applicable.
(2) Colposcopy of the cervix and vagina because of the common as-
sociation with other squamous intraepithelial lesions.
(3) For large lesions, a CT orMRI scan of the pelvis and groins is help-
ful to detect any enlarged lymph nodes in the groins or pelvis,
erosion into underlying bony structures, or other evidence of
metastatic disease.
(4) Routine full blood count, biochemical proﬁle, and chest
X-ray preoperatively.4.4. Clinical practice guidelines
The clinical ﬁndings should be recorded on a staging diagram
(e.g. Fig. 1). The ﬁndings according to the staging delineated in
Tables 1 and 2 are usually listed on the reverse side of the diagram.4.5. Treatment
4.5.1. Treatment of vulvar intraepithelial neoplasia
Various treatment modalities are available for treating intraepithelial
lesions of the vulva [7,8]. Once the diagnosis has been established, super-
ﬁcial local excision of the vulvar epitheliumwith a 0.5–1.0-cmmargin is
considered adequate for lesions of the lateral aspect of the vulva. Lesions
involving the labia minora may also be treated by local excision but may
respond favorably to laser vaporization. Laser is also appropriate for
clitoral and perianal lesions. Laser treatment of the hair-bearing skin of
the vulva will usually produce depigmentation and destruction of hair
follicles, with subsequent loss of hair growth. Large lesions may be
treated with a skinning vulvectomy and split-thickness skin graft. Level
of Evidence C
Two randomized controlled trials have shown promising results
with the topical immune response modiﬁer, imiquimod, with complete
response rates of 35–81% reported [9,10]. Long-term follow-up of pa-
tients in one of the studies showed good sustained beneﬁt, although
the number of patients in the study was small [9]. Level of Evidence A
Fig. 1. Vulvar staging diagram.
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Management of vulvar cancer must be individualized. There is no
standard operation and the emphasis should be on performing the
most conservative operation consistent with cure of the disease [3].
In considering surgical treatment options, it is necessary to consider
independently the most appropriate management of:
(1) The primary lesion.
(2) The groin lymph nodes.
In cases of locally advanced disease, treatment options for each site
should be considered independently and then in the context of the over-
all management of the patient, in order to select a treatment that will op-
timize the likelihood of cure and minimize treatment-related morbidity.4.5.3. Microinvasive vulvar cancer (Stage IA)
Stage IA carcinoma of the vulva is deﬁned as a single lesion measur-
ing 2 cm or less in diameter with a depth of invasion of 1.0 mm or less,
the depth being measured from the epithelial–stromal junction of the
most adjacent superﬁcial dermal papilla to the deepest point of inva-
sion. Lesions of this extent should be managed with radical localexcision. Groin dissection is not necessary for lesions of this type
[11,12]. Level of Evidence C
4.5.4. Early vulvar cancer
Tumors conﬁned to the vulva without suspicious lymph nodes, as
determined by clinical examination,with orwithout ultrasonic or radio-
logical assessment, may be considered early.
4.5.4.1. Management of the primary lesion (Fig. 2). To decrease psycho-
sexual morbidity, a more conservative operation than radical
vulvectomy usually is indicated. The procedure may be called a radical
local excision, and for localized lesions, this operation is as effective as
radical vulvectomy in preventing local recurrence [3,13–17].
Surgical removal should achieve lateral margins of at least 1 cm, and
the deep margin should be the inferior fascia of the urogenital dia-
phragm, which is co-planar with the fascia lata and the fascia over the
pubic symphysis [13,16–18].
If the lesion is close to the urethra, the distal 1 cmof the urethramay
be resected without jeopardizing urinary continence.
If there is associated VIN, this should be superﬁcially excised to con-
trol symptoms, to exclude other areas of superﬁcial invasion, and to
Fig. 2.Management of early vulvar cancer. * If there is associated VIN or lichen sclerosis,
these areas may be superﬁcially excised.
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true for differentiated VIN. Level of Evidence C4.5.4.2. Management of groin lymph nodes. Recurrence in the groin
carries a very high mortality; therefore, appropriate groin treatment
is the single most important factor in reducing mortality from early
vulvar cancer [3].
All patients with FIGO stage 1B or stage II lesions should have at least
an ipsilateral inguinofemoral lymphadenectomy. Level of Evidence C
The incidence of positive contralateral nodes in patients with small
lateral lesions and negative ipsilateral nodes is less than 1%, so unilateral
groin dissection is appropriate for such lesions [3].
Bilateral groin dissection should be performed for midline tumors,
and for those involving the anterior labia minora [19]. Large lateral
tumors should probably also have bilateral dissection, and deﬁnitely if
the ipsilateral nodes are positive [19].
Sentinel node excision is being increasingly practiced in many
centers following the Europeanmulticenter observational study on sen-
tinel node detection [20]. This procedure detects nodal metastasis in
most patients with regional spread of disease, and is associated with a
lower rate of lymphedema than complete lymphadenectomy. The
study, (GROINSS-V), involved 403 women with a unifocal tumor con-
ﬁned to the vulva less than 4 cm in diameter, stromal invasion more
than 1 mm, and clinically negative lymph nodes [20]. Sentinel nodes
were identiﬁed using blue dye and radiolabelled technetium. Lymphad-
enectomy was omitted in sentinel node negative women. Groin recur-
rences occurred in 2.3% of patients, with a median follow-up of 35
months. Overall disease-speciﬁc survivalwas 97% after 3 years andmor-
bidity was substantially reduced. Higher false-negative rates have been
reported in other studies [21–23].
Owing to the small but deﬁnite false-negative rate with sentinel
node biopsy, and the high risk of death if groin recurrence occurs,
some patients, properly informed of the risks and beneﬁts, will elect
to have a full groin dissection, despite the greater complication rate
[24–26]. Level of Evidence B4.5.4.3. Groin dissection. It is recommended that both inguinal and fem-
oral nodes be removed, as inguinal node dissection alone is associated
with a higher incidence of groin recurrence [27]. Level of Evidence A
The femoral nodes are situatedmedial to the femoral veinwithin the
fossa ovalis. There is no need to remove the fascia lata to dissect the
femoral nodes [28]. Groin dissection may be safely performed through
a triple incision approach, and this should improve primary healing
compared with an en bloc resection of the vulva and groins [29]. Level
of Evidence C
An en bloc approach may still be useful for clitoral or periclitoral
lesions. To avoid skin necrosis, all subcutaneous tissue above the super-
ﬁcial fascia must be preserved.
Groin dissection (with postoperative radiation for patients with
positive groin nodes) was found to be superior to groin irradiation in
one small randomized trial [30]. Pretreatment imaging that might
have detected grossly enlarged nodes was not performed in that early
trial and the radiation technique used was considered inadequate
to cover the at-risk inguinofemoral nodes [31]. Retrospective clinical
reviews have suggested that radiation alone can control microscopic
disease in the groins if adequate coverage of the inguinofemoral nodes
is conﬁrmed [32,33].
4.5.4.4. Management of patients with positive groin nodes. TheGynecolog-
ic Oncology Groupdemonstrated superior results for pelvic and inguinal
radiation comparedwith pelvic node dissection for patients who had an
inguinal lymphnode dissectionwithﬁndings of grossly positive ormore
than one positive node [34]. Level of EvidenceA. A recent retrospective,
multicenter German study also reported improved survival for patients
with positive groin nodes who received adjuvant radiotherapy directed
at the groins (positive/negative other ﬁelds) [35].
Several studies have emphasized the prognostic signiﬁcance of the
morphology of positive groin nodes, particularly the size of themetasta-
sis and the presence or absence of extracapsular spread [36–38].
Patients with one small lymph node metastasis do not appear to
beneﬁt from adjuvant radiation therapy; several series suggest that
their prognosis is good after inguinofemoral lymphadenectomy alone
[37–39], but the number of patients in most series is too small to draw
deﬁnitive conclusions. A multicenter Dutch study of 75 patients with
vulvar cancer and one positive lymph node of all sizes reported that
adjuvant radiation was only beneﬁcial if extracapsular spread was
present [40].
Reasonable indications for bilateral pelvic and groin irradiation in
patients with positive groin nodes would be:
• The presence of extracapsular spread.
• Two or more positive groin nodes. Level of Evidence B
An ongoing international prospective observational trial (GROINSS-V
II) is investigating the efﬁcacy of groin radiation, without inguinofemoral
lymphadenectomy, for patients with a single positive sentinel lymph
node 2 mm or less in diameter. Pending the results of this study, all
patients who have had a sentinel lymph node biopsy and are found
to have one or more positive nodes should be treated with a full
inguinofemoral lymph node dissection, followed by radiotherapy to
the groins and pelvis if indicated.
4.5.4.5. Radiation ﬁelds and doses. Inmost cases, ﬁelds should include the
inguinofemoral, external iliac, and internal iliac lymph nodes. The upper
border may be extended if there is extensive inguinal involvement or
suspicion of pelvic node metastasis.
One of a variety of radiation techniques can be selected, depending
on the patient’s body habitus and extent of disease. Treatments should
always be based on three-dimensional planning using high-quality CT
or MRI images.
Combined photon and electron techniques are often used to treat
the regional nodes, without overdosing the femoral heads. Care must
be taken to completely include both the superﬁcial and deep inguinal
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superﬁcial inguinal nodes byhigh-energy photon beams. If electron beams
areused, the energymust be sufﬁcient to cover the femoral nodes. In recent
years, some clinicians have begun to use intensity-modulated radiation
therapy (IMRT) or other inverse-planned, computer-controlled delivery
techniques to treat vulvar cancer. Although these techniques can reduce
acute radiation effects in skin and soft tissue, the treatment planning
and delivery are complex, and the opportunity for unanticipated
underdosage of the target is substantial, suggesting that these cases may
be best treated by clinicians who have considerable specialized expertise.
The dose of radiation is determined by the initial extent of regional
disease and any known residual. After a groin dissection with microscopic
inguinal metastases, 50 Gy in 1.8–2.0 Gy fractions is usually sufﬁcient.
If there are multiple positive nodes or if there is evidence of
extracapsular extension, doses up to 60 Gy may be given to a reduced
volume. Gross residual disease usually requires 60–70 Gy to achieve a
high probability of regional disease control.
The effectiveness of concurrent chemotherapy in the treatment of
groin and pelvic lymph nodes is unknown.
4.5.5. Advanced vulvar cancer
Patients with primary tumors extending beyond the vulva, or bulky
positive groin nodes are considered to have advanced vulvar cancer. For
such patients, multimodality treatment planning is particularly important.
4.5.5.1. Management of groin lymph nodes. It is desirable to determine the
status of the groin nodes prior to planning the overall treatment [3].
Pelvic CT or MRI should be part of the patient’s initial workup. These
studies are particularly helpful in suggesting the extent of inguinal or
pelvic lymphadenopathy (Fig. 3). Pelvic MRI can also provide useful
information about the anatomical extent of the primary lesion, but is
not mandatory.
If there are no suspicious nodes in the groin on CT scan, bilateral
inguinofemoral lymphadenectomymay be performed. If ﬁnal histologic
assessment reveals positive nodes, adjuvant radiation to the groin and
pelvis should follow the guidelines given for early stage disease. If the
nodes are negative, groin and pelvic radiation may be eliminated.
Alternatively, primary chemoradiation therapy may be used to treat
the primary tumor as well as the groin and pelvic nodes if surgery is
deemed inappropriate for the individual patient [32,33].Fig. 3.Management of clinically suspicious groin nodes.If nodes are clinically positive, a complete lymphadenectomy should
be avoided because full groin dissection together with postoperative
groin irradiation may result in severe lymphedema. Only enlarged
nodes from the groin and pelvis should be removed if feasible, and the
patient given postoperative groin and pelvic radiation [41]. Level of
Evidence C
If there are ulcerated or ﬁxed groin nodes, they should be resected if
not inﬁltrating muscle or femoral vessels, as determined by imaging
studies. If nodes are not felt to be resectable, they should be biopsied
to conﬁrm the diagnosis then treated with primary radiation, with or
without chemotherapy. If appropriate, the nodes may be resected fol-
lowing radiation if there has been an incomplete response (Fig. 4)
[42]. Level of Evidence C
4.5.5.2. Management of the primary tumor (Fig. 5). If it is possible to resect
the primary lesion with clear surgical margins and without sphincter
damage leading to urinary or fecal incontinence, primary surgical exci-
sion is usually the preferred treatment. It usually follows dissection of
the groins, although this is not mandatory.
If primary surgery would result in the need for a bowel or urinary
stoma, it is preferable to employ primary radiation therapy, some-
times followed by a more limited resection of the residual tumor or
tumor bed [43,44].
Chemoradiation has been used extensively for large lesions if surgi-
cal resection would damage central structures (anus, urethra); durable
complete responses without the need for post-treatment surgery have
been well described [45–49].
The groin nodes and pelvismay need to be included in the treatment
ﬁeld depending on the status of the groin nodes, as determined initially.
Treatment with neoadjuvant cisplatin and 5-ﬂuorouracil, or other
drug combinations, has been reported in small retrospective studies to
be effective for preservation of the anal sphincter and/or urethra in
patients with advanced vulvar cancer [50,51]. This approach deserves
further clinical research.
4.5.5.3. Radiation protocol. If the groin nodes are positive and meet the
requirements described earlier for adjuvant radiation, the initial radia-
tion treatment ﬁelds should include the pelvis, inguinal nodes, and pri-
mary site, which are treated to a total dose of at least 50 Gy. Care must
be taken to adequately cover the inguinal nodes.
Some clinicians prefer to treat in an open-leg position but care must
be taken to apply bolus to the vulva to avoid underdosage of potentially
involved skin regions.
Areas of gross disease or particularly high risk are usually boosted
either with appositional ﬁelds of electrons selected to provide an ade-
quate dose to the surface and at depth, or with conformal external
beam therapy. Gross vulvar disease probably requires 60–70 Gy to
achieve local control, although investigators are currently exploringFig. 4.Management of clinically obvious groin nodes.
Fig. 5.Management of advanced primary tumor. Treatment should usually follow dissec-
tion of the groins. Groin and pelvic radiation should follow standard indications.
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tween dose and local control remains somewhat uncertain. Level of
Evidence C
4.5.5.4. Close surgical margins. Most recurrences from vulvar cancer
occur on the vulva. Rouzier et al. [52] described two types of local recur-
rences, those at theprimary site and those at a remote site. In an analysis
of patients with vulvar cancer from the Royal Hospital for Women in
Sydney [13], primary site recurrences occurred with a median disease-
free interval of 21months, andwere associated with a histological mar-
gin of 8mmor less, as previously reported [16− 18]. Remote site recur-
rences occurred with a median disease-free interval of 69 months, and
were more commonly associated with lichen sclerosus. Although
some recent papers have not found an association between margin dis-
tance and local recurrence, these papers have not distinguished primary
from remote site recurrences [53,54].
Postoperative radiation is of beneﬁt for patients with close surgical
margins (less than 5mm), if themargins cannot be re-excised [55]. A re-
cent study of 205 patients with vulvar cancer from Boston reported that
the highest risk of vulvar recurrence was associated with margins of
5 mm or less (P = 0.002), and that patients who received a dose of
more than or equal to 56 Gy had a lower risk of relapse than those
who received less than or equal to 50.4 Gy (P b 0.05) [56].
In some cases, the positive margin may be boostedwith brachyther-
apy, although this technique requires experience to avoid an excessive
risk of necrosis. Alternatively, the operative bed may be treated with
an appositional electron ﬁeld or in some cases, carefully planned confor-
mal external beam irradiation. Level of Evidence C
5. Special situations
5.1. Vulvar melanoma
Vulvar melanoma is the second most common neoplasm of the
vulva. The majority of lesions involve the clitoris or labia minora. The
Clark or Breslow modiﬁcations to the micro staging system should be
used for the staging of vulvar melanoma rather than themore common
TNM/FIGO system. These systems measure the depth of invasion in
terms of the descriptive histology of the skin.
Any pigmented lesion on the vulva should be excised for diagnosis
unless it has been known to be present and unchanged for some years.
In line with trends toward more conservative surgery for cutaneous
melanomas, there is a trend toward more conservative resection ofvulvarmelanomas [57–59]. Primary lesions should be treated by radical
local excision, with margins around the lesion of at least 1 cm. Level of
Evidence C
The role of node dissection is also controversial, but the Intergroup
Surgical Melanoma Program has conducted a prospective, multi-
institutional randomized trial of elective node dissection versus obser-
vation for intermediate thickness cutaneous melanomas (1–4 mm)
[60]. There were 740 patients entered into the trial, and elective node
dissection resulted in a signiﬁcantly better survival for patients
60 years of age or younger, patients with tumors 1–2 mm thick, and
patients without tumor ulceration.
5.2. Bartholin’s gland cancer
Cancers arising in the Bartholin’s gland may be either transitional or
squamous types, arising from the duct, or an adenocarcinoma from the
gland itself. Adenoid cystic and adenosquamous variants have also been
reported. Adenocarcinomas of the vulva occur, on average, approxi-
mately a decade earlier than invasive squamous cancers. Frequently,
diagnosis is made after resection of what was thought to be a persisting
Bartholin’s cyst.
The standard approach for Bartholin’s gland carcinomas has been
radical vulvectomy and bilateral groin dissection. However, ipsilateral
groin dissection and radical hemi-vulvectomy may be equally effective
for early lesions [61]. Because these lesions are deep in the ischiorectal
fossa, surgical margins are more likely to be close, particularly for
bulky lesions, and postoperative radiation to the vulva may decrease
the likelihood of local recurrence [61]. Level of Evidence C
If the ipsilateral groin nodes are positive, bilateral groin and pelvic
radiation may decrease regional recurrence.
For adenoid cystic lesions, radical local excision alone is the treat-
ment of choice, with adjuvant local radiation recommended for positive
margins or perineural invasion [62]. Level of Evidence C
5.3. Paget’s Disease
This is predominantly an intraepithelial lesion, but on occasion it
may be associated with an underlying invasive adenocarcinoma. It is
usually of primary cutaneous origin from the vulva, but may be second-
ary to an anorectal, urothelial, or noncutaneous genital tract carcinoma
(e.g. endocervical or endometrial) [63].
The disease occurs predominantly in the menopausal or postmeno-
pausal population. Most patients will present with vulvar discomfort
and itching and on examination, an eczematoid, weeping lesion is
often seen. Diagnosis is usually conﬁrmed by biopsy, which will gener-
ally differentiate an intraepithelial from an invasive lesion [3,64].
Intraepithelial Paget’s disease requires superﬁcial local excision. It is
difﬁcult to obtain clear margins with this disease, as often the underly-
ing histologic change will extend far beyond the macroscopic lesion.
More recently, there has been a move to perform less radical resection
for intraepithelial lesions, with re-excision at a later date should lesions
become symptomatic or clinically visible [65]. Lesions that involve or
extend into the urethra or anus can be particularly difﬁcult to manage,
and may require laser therapy.
If there is an underlying adenocarcinoma, the invasive component
should be treated by radical local excision with margins of at least
1 cm. At least an ipsilateral inguinofemoral lymphadenectomy should
be performed for unilateral lesions, with adjuvant radiation following
the same indications as for squamous carcinomas [66]. Level of
Evidence C
6. Pathology
The surgical specimen should be correctly orientated and photo-
graphed. Photographs should be used to indicate the origin of tissue
blocks. The size of the specimen should be measured and the
S82 N.F. Hacker et al. / International Journal of Gynecology and Obstetrics 131 (2015) S76–S83dimensions of any visible tumormeasured. Themacroscopic tumor-free
surgical margins should be measured. Sections are taken through the
tumor tomeasure tumor depth. Sections should be taken from urethral,
anal, and vaginal resection margins.
Lymph nodes should be carefully dissected out and the site from
which they are removed recorded. A full cross-section of each lymph
node should be embedded.
The following histological points should be noted:
(a) Tumor type: keratinizing, basaloid, bowenoid.
(b) Depth of invasion: measured from the epithelial–stromal junc-
tion of the adjacent dermal papilla to the deepest point of inva-
sion by the tumor.
(c) Tumor grade.
(d) Histological measurement of tumor-free margins and statement
as to whether the tumor is completely excised.
(e) Presence or absence of perineural or vascular space invasion.
(f) Nature of the adjacent nonmalignant squamous epithelium: VIN,
lichen sclerosus, squamous hyperplasia, HPV-associated changes.
(g) Sites and number of nodes examined and number of positive
nodes. Presence or absence of extracapsular extension.
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